OHR Pharma shares soar as investors approve merger with NeuBase

NeuBase Therapeutics

10/07/2019 18:44

** Shares of eye drug developer  OHRP.O  up 35.5 at $5;
stock among top percentage gainers across exchanges
    ** Co says all proposals related to its proposed merger with
privately held NeuBase Therapeutics Inc were approved by Ohr's
stockholders at a special meeting  urn:newsml:reuters.com:*:nGNX7yVGRv
    ** In Jan, co signed merger agreement with NeuBase to use
RNA gene silencing technology for developing treatments for rare
genetic diseases 
    ** On closing of deal, combined co to take NeuBase's name
and be listed on Nasdaq under the symbol "NBSE"; NeuBase
shareholders to own ~80 pct of the merged entity
    ** Companies expect deal close during week of July 15
    ** Proposed merger remains subject to customary closing
conditions and regulatory approvals
    ** Up to Tuesday's close, stock had more than doubled YTD

 (Reporting by Tamara Mathias in Bengaluru)
 ((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 1208; Reuters Messaging:
tamara.mathias.thomsonreuters.com@reuters.net))